Articles tagged with Drug Design
Jeffery W. Kelly's work focuses on designing and utilizing small molecules to prevent neurodegenerative diseases similar to Alzheimer's but more rare. His team's molecular braces are now in preclinical trials for disorders like familial amyloid polyneuropathy.
UCB-Bioproducts is providing commercial quantities of bivalirudin for Angiomax, a thrombin-specific anticoagulant. The company's unique process technology enables the production of synthetic peptide-based APIs, and its regulatory support ensures compliance with FDA regulations.
Researchers have uncovered a biological program that prevents the development of pathogenic fungi under nitrogen-poor conditions. The unfolded protein response (UPR) mediates this morphological response and can be targeted to develop new anti-fungal therapies.
The virtual reality experience, Paved with Fear, simulates daily activities for psychiatrists to grasp the impact of auditory and visual hallucinations. Developed in collaboration with patients, this innovative technology provides a unique understanding of the condition, ultimately enhancing treatment effectiveness.
The journal features novel approaches to analyzing complex peptides, such as pramlintide, and developing injectable implants for sustained drug release. Liposomes are also explored as carriers for antimicrobial peptides like Leucinostatin A.
Scientists propose a revised four-point location model to explain how proteins discriminate between mirror-image molecules. This new understanding could significantly impact drug design, as it challenges the long-held three-point attachment model and may lead to more effective treatment strategies.
The event will cover hormone replacement therapies, phytoestrogens, common herbs and dietary supplements, and health promotion strategies. UCSF experts will provide guidance on managing menopausal symptoms and maintaining long-term health.
For the first time, researchers have designed a working molecular motor that can convert chemical energy into controlled motion. This breakthrough advances miniaturization technology to the single molecule level, with potential applications in understanding diseases and developing new treatments.
A human factors approach to interface design significantly reduces errors in patient-controlled analgesia. The redesigned device shows a 55% reduction in errors, an 18% improvement in performance time, and a strong preference among nurses.
Researchers have discovered the precise three-dimensional shape of the complex between tamoxifen and the estrogen receptor. This clarifies how estrogens turn on genes and shows precisely how tamoxifen blocks this process, setting the stage for intentional drug design with precise action.
The American Association of Pharmaceutical Scientists has recognized eight researchers with awards for their outstanding contributions to the field. Sung Wan Kim received the AAPS-Dale E. Wurster Research Award in Pharmaceutics for his work on controlled drug delivery systems, while Vincent H.L. Lee was honored with the Distinguished S...
A new approach to experimentation using computer simulation and rapid prototyping could significantly reduce development cost and time in the computer, pharmaceutical, and chemical industries. The study found that firms can save millions of dollars by switching between these methods at the optimal point.
Researchers at Yale University are using computer simulations to design more effective pharmaceuticals by optimizing chemical binding to target proteins. This approach has the potential to improve treatment outcomes for diseases such as dementia, diabetes, and spinal cord injuries.
The Cook GR II Coronary Stent has received FDA clearance for treatment of acute or threatened vessel closure in patients with failed interventional therapy. The stent features a flat metal design and low profile for improved radial strength and trackability.
A prison-release program for HIV-positive women successfully links clients with medical care and substance-abuse treatment on release from prison. The program resulted in a more than 50-percent decrease in the recidivism rate, with women experiencing reduced rates of return to prison within six months and one year.
A large study published in the New England Journal of Medicine found that patients with mild asthma do not need to take albuterol regularly. The study suggests that using albuterol only during symptoms can effectively manage asthma without negative consequences.